lorazepam- Lorazepam injection

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

Lorazepam (UNII: O26FZP769L) (Lorazepam - UNII:O26FZP769L)

Verfügbar ab:

Watson Laboratories, Inc.

INN (Internationale Bezeichnung):

Lorazepam

Darreichungsform:

INJECTION

Zusammensetzung:

2 mg in 1 mL

Verabreichungsweg:

INTRAMUSCULAR

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

Status Epilepticus Lorazepam injection is indicated for the treatment of status epilepticus. Preanesthetic Lorazepam injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (seePRECAUTIONS, Information for Patients ). Lorazepam injection is contraindicated in patients with a known sensitivity to benzodiazepines or its vehicle (polyethylene glycol, propylene glycol, and benzyl alcohol), in patients with acute narrow-angle glaucoma, or in patients with sleep apnea syndrome.  It is also contraindicated in patients with severe respiratory insufficiency, except in those patients requiring relief of anxiety and/or diminished recall of events while being mechanically ventilated. The use of lorazepam inj

Produktbesonderheiten:

Lorazepam Injection USP, 2 mg/mL is available in 1 mL single dose vials in cartons of 10 or 10 mL multiple dose vials in cartons of 10. For IM or IV injection. Store in a refrigerator. Protect from light. Use carton to protect contents from light. Literature revised: April 2004 Product Nos.: 1013-01, 1013-10 Watson Laboratories, Inc. Corona, CA 92880 USA

Fachinformation

LORAZEPAM- LORAZEPAM INJECTION
WATSON LABORATORIES, INC.
----------
LORAZEPAM INJECTION USP C-IV
RX ONLY
DESCRIPTION
Lorazepam, a benzodiazepine with antianxiety, sedative, and
anticonvulsant effects, is intended for the
intramuscular or intravenous routes of administration. It has the
chemical formula: 7-chloro-5 (2-
chlorophenyl)-1,3-dihydro-3-hydroxy-2_H_-1,4-benzodiazepin-2-one. The
molecular weight is 321.16,
and the C.A.S. No. is [846-49-1]. The structural formula is:
Lorazepam is a nearly white powder almost insoluble in water. Each mL
of sterile injection contains 2.0
mg of lorazepam, 0.18 mL polyethylene glycol 400 in propylene glycol
with 2.0% benzyl alcohol as
preservative.
CLINICAL PHARMACOLOGY
Lorazepam interacts with the γ-aminobutyric acid
(GABA)-benzodiazepine receptor complex, which is
widespread in the brain of humans as well as other species. This
interaction is presumed to be
responsible for lorazepam's mechanism of action. Lorazepam exhibits
relatively high and specific
affinity for its recognition site but does not displace GABA.
Attachment to the specific binding site
enhances the affinity of GABA for its receptor site on the same
receptor complex. The
pharmacodynamic consequences of benzodiazepine agonist actions include
antianxiety effects, sedation,
and reduction of seizure activity. The intensity of action is directly
related to the degree of
benzodiazepine receptor occupancy.
EFFECTS IN PRE-OPERATIVE PATIENTS
Intravenous or intramuscular administration of the recommended dose of
2 mg to 4 mg of lorazepam
injection to adult patients is followed by dose-related effects of
sedation (sleepiness or drowsiness),
relief of preoperative anxiety, and lack of recall of events related
to the day of surgery in the majority
of patients. The clinical sedation (sleepiness or drowsiness) thus
noted is such that the majority of
patients are able to respond to simple instructions whether they give
the appearance of being awake or
asleep. The lack of recall is relative rather than absolute, as
determine